Navigation Links
Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
Date:11/29/2011

NEWARK, Del., Nov. 29, 2011 /PRNewswire-iReach/ --  Quantum Leap Innovations announced today the appointment of Michael A. Cusumano to their Board of Directors.  Michael Cusumano is the Sloan Management Review Distinguished Professor of Management at the Massachusetts Institute of Technology's Sloan School of Management, with a joint appointment in the MIT Engineering Systems Division. His seminal 2010 book, STAYING POWER, covers six enduring principles for managing strategy and innovation in an uncertain world.

(Photo:  http://photos.prnewswire.com/prnh/20111129/CG13879)

"We are honored to have someone of Dr. Cusamano's stature agree to join our board," said Quantum Leap founder and CEO Joseph Budner Elad. "His support validates our vision of Pattern Based Analytics and the importance of our technology in today's uncertain world."

"It is with great pleasure and excitement that I join the Quantum Leap board," says Dr. Cusumano. "I have known the principals in the company for many years and have closely followed the evolution of their work in data analysis.  The pattern-based analytics approach took years to develop. It significantly improves our ability to visualize and make sense of complex data sets and then apply these insights to a wide variety of business and other applications."

About Michael Cusumano:

Michael Cusumano specializes in strategy, product development, and entrepreneurship in the computer software industry, as well as automobiles and consumer electronics. He teaches courses on The Software Business and Digital Platforms as well as Strategic Management and Managing Technological Innovation and Entrepreneurship.

Professor Cusumano earned his B.A. degree from Princeton and his Ph.D. from Harvard.  He completed a pos
'/>"/>

SOURCE Quantum Leap Innovations
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
3. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
4. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
5. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
6. Michael J. Fox Foundation Awards Grant to Zymes LLC
7. Dr. Michael Hanley Joins Celtaxsys as CEO
8. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
9. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
10. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
11. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... DUBLIN and BOSTON , ... ACT ), a leading global specialty pharmaceutical company, and ... been granted an exclusive option to acquire Rhythm,s wholly ... (RM-131), a peptide ghrelin agonist, for the treatment of ... Rhythm has completed a successful Phase 2 trial ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... the University of Illinois helped lead a collaborative ... for serious Staphylococcus aureus (Staph) infections. The research, ... of Science magazine, comes at a time when ... methicillin-resistant S. aureus) are spreading in epidemic proportions ...
... Pipeline ... Continues to Mature, SOUTH SAN FRANCISCO, Calif., Feb. 14 ... full,year and fourth quarter ended December 31, 2007., Revenues for the ... revenues for the full year was primarily due to,revenue recognition associated with ...
... IRVINE, Calif., Feb. 14 SectorWatch.biz announces the,availability ... the news and,driving markets today., Investors can ... by,visiting: http://www.SectorWatch.biz -- Click on MarketStats, ... include:,CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), ...
Cached Biology Technology:New approach may render disease-causing staph harmless 2New approach may render disease-causing staph harmless 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... with research associate Jerilyn Walker and assistant professor Miriam Konkel, ... ancient jumping genes called Alu, which are more than 16 ... the Zoological Society of San Diego and the Institute of ... open access journal Mobile DNA . These tiny ...
... are being investigated as a way of improving drug response ... launched today (Monday). Scientists at the Cancer Research UK ... (ECMC) in Leicester will investigate whether tablets containing curcumin ... to the standard treatment for bowel cancer that has spread. ...
... is available in German . Halle/Saale. In ... special strategies. These differ in part considerably from the propagation ... Dr. Sonja Knapp of the Helmholtz Centre for Environmental Research ... current issue of the scientific journal Ecology Letters . ...
Cached Biology News:LSU research finds orangutans host ancient jumping genes 2Trial launched into curry chemical's cancer-fighting properties 2Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
Biology Products: